Industry news

AstraZeneca considers bid for Medivation and with it Xtandi

Read time: 1 mins

Last updated:18th Apr 2016

Published:18th Apr 2016

Source: Pharmawand

AstraZeneca is considering a �7 billion bid for Medivation according to the Sunday Times. AstraZeneca has interest in the company and its prostate cancer drug Xtandi (enzalutamide) for sometime. An offer from Sanofi for Medivation was rejected by that companys' board recently and Sanofi may come back with a hostile bid.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Xoma Corporation announces completion of acquisition of shares of Kinnate Biopharma Inc.

XOMA Corporation, a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health

1 mins

Industry news

Regeneron Pharma and Mammoth Biosciences collaborate on CRISPR based gene editing therapies.

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types

1 min

Industry news

Antibe Therapeutics has receiver appointed.

Antibe Therapeutics Inc. announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) was heard before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024 and the decision was reserved

1 min

See all news